It's time for the IN VIVO Blog's Sixth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

GlaxoSmithKline is following some of its big pharma peers to key innovation hubs in the U.S. by opening satellite R&D centers in ...

Skeptical kitten wants to see what comes out the other side. Single-asset companies. Asset-centric funds. Project-based financing. Call ...

  Since when did “LP” stand for “Lavish Pharma” – as in, lavishing cash upon the life science venture world? Everyone in our corner of...

GlaxoSmithKline has been out ahead of other big pharmas when it comes to investing in venture funds. Its deal with Avalon Ventures repres...